["Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain - ScienceDirect", "SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies | bioRxiv", "Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display | bioRxiv", "Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function | Nature Structural & Molecular Biology", "Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants | Cell Discovery", "Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike | Nature", "A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model | bioRxiv", "Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality | bioRxiv", "Error - Cookies Turned Off", "AAAS", "Redirecting", "A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes | bioRxiv", "RCSB PDB - 7EAN: immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 6D6", "AAAS", "The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates | bioRxiv", "A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration | bioRxiv", "Evolution of antibody immunity to SARS-CoV-2 | Nature", "AAAS", "A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 | Research Square", "Broad sarbecovirus neutralization by a human monoclonal antibody | Nature", "AAAS", "The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates | eLife", "AAAS", "Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries | Cell Discovery", "Convergent antibody responses to SARS-CoV-2 in convalescent individuals | Nature", "Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies | bioRxiv", "Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2 | bioRxiv", "RCSB PDB - 7DD2: S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab.", "AAAS", "Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2 | Nature Communications", "", "Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses | bioRxiv", "AAAS", "Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain | bioRxiv", "mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants | Nature", "Naive human B cells can neutralize SARS-CoV-2 through recognition of its receptor binding domain | bioRxiv", "Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2 | bioRxiv", "Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors", "Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants | bioRxiv", "RCSB PDB - 7DPM: Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab", "Potent synthetic nanobodies against SARS-CoV-2 and molecular basis for neutralization | bioRxiv", "Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody | bioRxiv", "CN112094342A - Alpaca source nano antibody combined with SARS-CoV-2RBD \n        - Google Patents", "RCSB PDB - 7KXK: SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-\"up\"-1-\"down\" conformation", "CN111732655A - RBD-targeted high-neutralization-activity anti-SARS-CoV-2 fully-humanized monoclonal antibody and application thereof \n        - Google Patents", "CN111825762A - Nano antibody of S protein RBD structure domain of anti SARS-COV-2 virus and its use \n        - Google Patents", "CN111875700A - Single-chain antibody of anti SARS-COV-2 virus N protein and its use \n      - Google Patents", "CN111995674A - anti-COVID-19 virus neutralizing antibody mhC3, humanized antibody and application thereof \n        - Google Patents", "CN112062838A - Neutralizing single-domain antibody for resisting novel coronavirus SARS-Cov-2 and application thereof \n        - Google Patents", "CN112062840A - Nano antibody based on novel coronavirus S protein and application thereof \n      - Google Patents", "US10822379B1 - Molecules that bind to SARS-CoV-2 \n        - Google Patents", "Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite - ScienceDirect", "Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD - ScienceDirect", "LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection | bioRxiv", "CN111848789A - Single chain antibody for resisting SARS-COV-2 virus S protein and its use \n        - Google Patents", "CN111875701A - Single-chain antibody of SARS-CoV-2 virus and its use \n      - Google Patents", "CN111909260A - New coronavirus RBD specific monoclonal antibody and application \n        - Google Patents", "CN111909261A - New coronavirus RBD specific monoclonal antibody and application \n        - Google Patents", "CN111909262A - New coronavirus RBD specific monoclonal antibody and application \n        - Google Patents", "CN111909263A - New coronavirus RBD specific monoclonal antibody and application \n        - Google Patents", "CN111925440A - New coronavirus RBD specific monoclonal antibody and application \n      - Google Patents", "CN111925441A - New coronavirus RBD specific monoclonal antibody and application \n      - Google Patents", "CN111925442A - New coronavirus RBD specific monoclonal antibody and application \n      - Google Patents", "CN111925443A - New coronavirus RBD specific monoclonal antibody and application \n      - Google Patents", "CN111925444A - New coronavirus RBD specific monoclonal antibody and application \n      - Google Patents", "Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection | Cell Research", "Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein | Nature Medicine", "High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme | Scientific Reports", "A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD | bioRxiv", "Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants | bioRxiv", "Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry | bioRxiv", "Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergence | bioRxiv", "A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies | bioRxiv", "Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a na\u00efve human antibody library | bioRxiv", "AAAS", "CN111978395A - Monoclonal antibody against novel coronavirus RBD domain antigen \n      - Google Patents", "Discovery of nanobodies against SARS-CoV-2 and an uncommon neutralizing mechanism | bioRxiv", "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody | Nature", "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses | Nature", "Error - Cookies Turned Off", "AAAS", "Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody | bioRxiv", "AAAS", "Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2 | Nature Communications", "SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape | Nature", "Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient | bioRxiv", "Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 | Nature Structural & Molecular Biology", "AAAS", "Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual | bioRxiv", "AAAS", "Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection - ScienceDirect", "Redirecting", "AAAS", "Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant - ScienceDirect", "Structure of a germline-like human antibody defines a neutralizing epitope on the SARS-CoV-2 spike NTD | bioRxiv", "Mouse Antibodies with Activity Against the SARS-CoV-2 D614G and B.1.351 Variants | bioRxiv", "Structure-based development of human antibody cocktails against SARS-CoV-2 | Cell Research", "The antigenic anatomy of SARS-CoV-2 receptor binding domain - ScienceDirect", "Antibody evasion by the P.1 strain of SARS-CoV-2 - ScienceDirect", "Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals | bioRxiv", "Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients\u2019 B Cells - ScienceDirect", "B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV - ScienceDirect", "Fast isolation of sub-nanomolar affinity alpaca nanobody against the Spike RBD of SARS-CoV-2 by combining bacterial display and a simple single-step density gradient selection | bioRxiv", "Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking | bioRxiv", "Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution | bioRxiv", "", "Human single-chain antibodies neutralize SARS-CoV-2 variants by engaging an essential epitope of the spike: a new weapon against COVID-19 | bioRxiv", "Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency | bioRxiv", "Accelerated Antibody Discovery Targeting the SARS-CoV-2 Spike Protein for COVID-19 Therapeutic Potential | bioRxiv", "Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants | Nature", "Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies - ScienceDirect", "A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection | The Journal of Immunology", "Human neutralizing antibodies elicited by SARS-CoV-2 infection | Nature", "Identification of single-chain antibody fragments specific against SARS-associated coronavirus from phage-displayed antibody library - ScienceDirect", "AAAS", "Fragment-based computational design of antibodies targeting structured epitopes | bioRxiv", "Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies | bioRxiv", "RCSB PDB - 7EAM: immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6", "RCSB PDB - 7CR5: Complex structure of a human monoclonal antibody with SARS-CoV-2 nucleocapsid protein NTD", "Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes", "Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2 - ScienceDirect", "LY-CoV1404 potently neutralizes SARS-CoV-2 variants | bioRxiv", "A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope | bioRxiv", "Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects | bioRxiv", "Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection | PNAS", "Extremely potent human monoclonal antibodies from COVID-19 convalescent patients - ScienceDirect", "Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition | bioRxiv", "Isolation and identification of an scFv antibody against nucleocapsid protein of SARS-CoV - ScienceDirect", "Figure 2 from 645 Duan.qxp | Semantic Scholar", "Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11 - ScienceDirect", "Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens - ScienceDirect", "A dominant antigenic epitope on SARS-CoV spike protein identified by an avian single-chain variable fragment (scFv)-expressing phage - ScienceDirect", "Chicken single-chain variable fragments against the SARS-CoV spike protein - ScienceDirect", "Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection | PNAS", "Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions - ScienceDirect", "A human monoclonal antibody blocking SARS-CoV-2 infection | Nature Communications", "Structural basis for broad coronavirus neutralization | Nature Structural & Molecular Biology", "Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice - ScienceDirect", "AAAS", "A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes | Nature Communications", "Therapy with a Severe Acute Respiratory Syndrome\u2013Associated Coronavirus\u2013Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters | The Journal of Infectious Diseases | Oxford Academic", "Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein | Nature Communications", "Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen | PNAS", "Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway", "Structural Insights into Immune Recognition of the Severe Acute Respiratory Syndrome Coronavirus S Protein Receptor Binding Domain - ScienceDirect", "Structural Bases of Coronavirus Attachment to Host Aminopeptidase N and Its Inhibition by Neutralizing Antibodies", "Sybodies targeting the SARS-CoV-2 receptor-binding domain | bioRxiv", "Evaluation of candidate vaccine approaches for MERS-CoV | Nature Communications", "AAAS", "Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse\u00ae - ScienceDirect", "Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus - ScienceDirect", "DEFINE_ME", "Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody | Nature Communications", "AAAS", "DEFINE_ME", "WO2016138160 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE", "Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor | Cellular & Molecular Immunology", "A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein | Cell Research", "Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset | The Journal of Infectious Diseases | Oxford Academic", "Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals | bioRxiv", "Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants", "Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient | The Journal of Infectious Diseases | Oxford Academic", "Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2 | Communications Biology", "", "Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice | PNAS", "A human SARS-CoV neutralizing antibody against epitope on S2 protein - ScienceDirect", "Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades ago | bioRxiv", "Rapid generation of potent antibodies by autonomous hypermutation in yeast | bioRxiv", "CN111333722A - SARS-CoV-2 inhibitor and its application \n      - Google Patents", "CN111423508A - Separated SARS-CoV-2 protein binding molecule for resisting virus infection \n        - Google Patents", "CN111620945A - Monoclonal antibody or derivative thereof for resisting novel coronavirus \n        - Google Patents", "CN111647076A - Neutralizing single-domain antibody for resisting novel coronavirus SARS-Cov-2 and application thereof \n        - Google Patents", "CN111647077A - Novel coronavirus (SARS-COV-2) spike protein binding molecule and application thereof \n        - Google Patents", "CN111647079A - Neutralizing antibody for resisting novel coronavirus N protein \n        - Google Patents", "CN111662379A - Antibody for resisting novel coronavirus, preparation method and application \n        - Google Patents", "CN111690058A - Antibodies with neutralizing activity against coronaviruses and uses thereof \n        - Google Patents", "CN111690059A - Monoclonal antibody 1D7 for resisting SARS-CoV-2 \n      - Google Patents", "CN111718411A - Monoclonal antibody 1F2 for resisting SARS-CoV-2 \n        - Google Patents", "CN111732654A - Monoclonal antibody 1E10 for resisting SARS-CoV-2 \n        - Google Patents", "CN111778218A - Phage display antibody library and monoclonal antibody aiming at novel coronavirus SARS-CoV-2 obtained based on panning of phage display antibody library \n        - Google Patents", "CN111793129A - Antibody or antigen binding fragment thereof specifically binding to coronavirus \n        - Google Patents", "AAAS", "RCSB PDB - 7CDI: Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD", "RCSB PDB - 7CJI: Photosystem II structure in the S1 state", "Development of Multivalent Nanobodies Blocking SARS CoV 2 Infection by Targeting RBD of Spike Protein | Research Square", "A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro | bioRxiv", "DEFINE_ME", "An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction | Nature Communications", "A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes | Nature Communications", "Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain | Nature Communications", "Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies | Scientific Reports", "Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers | Nature Communications", "SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface | Nature Communications", "Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection | Nature Communications", "Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants | bioRxiv", "Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis - ScienceDirect", "Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2 | National Science Review | Oxford Academic", "Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike - ScienceDirect", "Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics | Nature Communications", "Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants | Cell Research", "DEFINE_ME", "Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection | Nature", "AAAS", "Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies | bioRxiv"]